Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ARCHIVE
T-DM1 Significantly Extends PFS in HER2-Positive Metastatic Breast Cancer: Roche
Roche has announced that its investigational drug T-DM1 (trastuzumab emtansine) significantly increased progression-free survival (PFS) in a randomized, multicenter, international clinical trial that compared T-DM1 monotherapy with the combination of Herceptin (trastuzumab) and docetaxel. T-DM1 is an antibody-drug conjugate (ADC)…
To read the full story
ARCHIVE
- Pharmaceutical Industry Salary Survey 2011
December 26, 2011
- AFII Grants France-Japan Investment Award to sanofi-aventis, Canon
December 19, 2011
- Plan Like Your Life Depended on It… It Just Might!
December 5, 2011
- Interviewing and Hiring: Strong Character Plus Good Attitude Equals Great Potential
November 14, 2011
- A Cry from the Next Generation of Japanese Pharmaceutical Executives
October 24, 2011
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…